Key Points
- Regeneron director Arthur Ryan sold 100 shares on Feb. 9 at an average price of $778.53 for $77,853, trimming his stake by 0.56% to 17,803 shares (disclosed in an SEC filing).
- Regeneron beat Q4 expectations with EPS of $11.44 (vs. $10.74 est.) and revenue of $3.88B (vs. $3.76B est.), and the company trades with a market cap around $81.9B and a P/E of ~18.7.
- The company raised its quarterly dividend to $0.94 (annualized $3.76, ~0.5% yield), with an ex-dividend/record date of Feb. 20 and payment on Mar. 5.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) Director Arthur Ryan sold 100 shares of the company's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the sale, the director owned 17,803 shares in the company, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Regeneron Pharmaceuticals Price Performance
NASDAQ:REGN opened at $778.97 on Thursday. The company has a 50 day moving average price of $759.25 and a 200-day moving average price of $662.51. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The firm has a market cap of $81.87 billion, a price-to-earnings ratio of 18.74, a price-to-earnings-growth ratio of 2.03 and a beta of 0.40. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm's revenue was up 2.5% on a year-over-year basis. During the same quarter last year, the business earned $12.07 earnings per share. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.
Regeneron Pharmaceuticals Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. Regeneron Pharmaceuticals's payout ratio is currently 8.47%.
Institutional Trading of Regeneron Pharmaceuticals
Several large investors have recently bought and sold shares of REGN. WPG Advisers LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 25 shares during the last quarter. Salomon & Ludwin LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter worth approximately $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $31,000. Board of the Pension Protection Fund purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $31,000. Finally, Entrust Financial LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on REGN shares. Wells Fargo & Company boosted their price target on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an "equal weight" rating in a report on Monday, February 2nd. Morgan Stanley boosted their target price on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an "equal weight" rating in a research note on Monday, February 2nd. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a "buy" rating for the company in a research report on Monday, February 2nd. BMO Capital Markets lifted their price objective on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an "outperform" rating in a report on Thursday, December 4th. Finally, Cantor Fitzgerald increased their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an "overweight" rating in a report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $793.81.
Check Out Our Latest Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Company Profile
(
Get Free Report)
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
